Fig. 2: miR-30c inhibits FANCF and REV1 expression by targeting the 3′-UTRs of FANCF and REV1. | Cell Death & Disease

Fig. 2: miR-30c inhibits FANCF and REV1 expression by targeting the 3′-UTRs of FANCF and REV1.

From: Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response

Fig. 2

a qRT-PCR and b Western blot analyses showing the mRNA and protein expression of REV1 and FANCF in untreated MCF-7 and MDA-MB-231 cells (blank), as well as cells transfected with miR-30a, miR-30b, miR-30c, miR-30d, miR-30e mimic and negative control (NC, scrambled control oligonucleotides). **p < 0.01 vs. NC group. c The REV1 and FANCF 3′UTR binding sites of miR-30c and the REV1 and FANCF 3′UTR mutation sites in the mutated luciferase plasmid. d Dual-luciferase activity in 293 T cells transfected with miR-30c mimic (20 nM), NC (20 nM) and a wild-type or mutated 3′UTR of REV1 or FANCF, **p < 0.01 vs. NC group. NS indicates no significant difference. NC: negative control, scrambled control oligonucleotides. e Western blot analysis showing the protein expression of REV1, FANCF, and FANCD2 in MCF-7 and MDA-MB-231 cells transfected with miR-30c inhibitors (20 nM) or the NC inhibitor (20 nM) and untreated MCF-7 and MDA-MB-231 cells (Blank). The graph showing the statistical results is located on the right. *p < 0.05, **p < 0.01 vs. Inh-NC group. Data represent the mean ± SD of three independent experiments

Back to article page